Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
The aggregate gross proceeds to Apogee from the offering are expected to be approximately $420.0 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee, excluding any exercise of the underwriters’ option to purchase additional shares.
- The aggregate gross proceeds to Apogee from the offering are expected to be approximately $420.0 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee, excluding any exercise of the underwriters’ option to purchase additional shares.
- The offering is expected to close on March 12, 2024, subject to the satisfaction of customary closing conditions.
- In addition, Apogee has granted the underwriters a 30-day option to purchase up to an additional 1,016,128 shares of common stock at the public offering price, less underwriting discounts and commissions.
- Jefferies, BofA Securities, Goldman Sachs & Co. LLC, TD Cowen and Stifel are acting as joint book-running managers for the offering.